Pathkey.AI (ASX: PKY) Raises $2.8 Million and Appoints Sam Weiss

Pathkey.AI has secured firm commitments for a $2.8 million placement and appointed former Altium chairman Sam Weiss as a strategic adviser. Weiss also cornerstoned the raising, which targets institutional and sophisticated investors.

The new capital will primarily accelerate development and commercial activity for Chipforge, Pathkey’s AI-powered semiconductor design platform. Funds will also support existing assets, broader business development and working capital.

Placement Terms and Fees

Pathkey will issue 100 million new fully paid ordinary shares at $0.028 each. Settlement is scheduled for 19 August 2026, with allotment expected around 20 August.

The company will issue the securities under its existing capacity in ASX Listing Rules 7.1 and 7.1A. Accordingly, the announcement does not flag a shareholder vote for the placement.

Blue Ocean Equities, 708 Capital and Sandton Capital acted as joint lead managers. They are entitled to a fee equal to 6% of all funds raised.

Blue Ocean will also act as bookrunner. It will receive 10 million unlisted options exercisable at $0.05 and expiring on 17 December 2027.

The $2.8 million figure is before transaction costs. The issue will expand Pathkey’s share count by 100 million shares, although the announcement provides no resulting ownership percentages.

Weiss Brings Altium Experience

Weiss served as Altium’s non-executive chairman from 2007 until 2024. During that period, Altium developed from a Sydney-based software company into a global printed circuit board design software provider.

His chairmanship concluded with Renesas Electronics acquiring Altium for approximately A$9.1 billion in cash. Pathkey is linking that background to Chipforge’s position in the adjacent semiconductor design software market.

Weiss will advise Pathkey’s chief executive and the Chipforge team. As part of his engagement, he will receive 40 million performance rights under the company’s incentive plan.

Those rights will vest in four equal tranches after six, 12, 24 and 36 months of service. This structure ties the award to a multi-year advisory period.

Capital Directed Toward Chipforge

Chipforge is developing an AI-native design and verification platform for FPGA and ASIC targets. Its proposed workflow spans design intent, generated register transfer level code, verification, simulation and sign-off.

Pathkey says these semiconductor workflows remain fragmented and constrained by specialist talent availability. Chipforge is designed to apply AI-based automation across that process.

The platform sits alongside TrialKey, which focuses on clinical trial design and optimisation. Both use an agent-based architecture combining large language models with neuro-symbolic reasoning.

Under that approach, AI agents generate candidate solutions and assess them against defined objectives. They then refine those solutions through reinforcement-driven optimisation.

Immediate Corporate Steps

Pathkey lodged an Appendix 3B covering the placement alongside the announcement. The release also lifted the trading halt applied at the start of trading on 12 August 2026.

The placement provides funding for technology development, marketing and business development. Its commercial impact will depend on how Pathkey advances Chipforge and its other programs using the new capital.